Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 101–200 of 4,108
Determinants of bone strength and quality in diabetes mellitus in humans
Farr, J. N., & Khosla, S. (2016) · Bone · doi:10.1016/j.bone.2015.07.027 · Cited by 192
An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis
Schini, M., Johansson, H., Harvey, N. C., Lorentzon, M., Kanis, J. A., & McCloskey, E. V. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02219-9 · Cited by 194
Li, K., Wang, X.-F., Li, D.-Y., Chen, Y.-C., Zhao, L.-J., Liu, X.-G., Guo, Y.-F., Shen, J., Lin, X., Deng, J., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s157523 · Cited by 191
Low Vitamin D Status: Definition, Prevalence, Consequences, and Correction
Binkley, N., Ramamurthy, R., & Krueger, D. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.008 · Cited by 189
The clinical epidemiology of male osteoporosis: a review of the recent literature
Nelson, R., Willson, T., Nelson, S., Newbold, J., & LaFleur, J. (2015) · Clinical Epidemiology · doi:10.2147/clep.s40966 · Cited by 190
LeFevre, M. L., & on behalf of the U.S. Preventive Services Task Force* (2015) · Annals of Internal Medicine · doi:10.7326/m14-2450 · Cited by 190
State of the art in osteoporosis risk assessment and treatment
Liu, J., Curtis, E. M., Cooper, C., & Harvey, N. C. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01041-6 · Cited by 189
Maria, S., & Witt‐Enderby, P. A. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12116 · Cited by 189
Miele, E., Shamir, R., Aloi, M., Assa, A., Braegger, C., Bronsky, J., de Ridder, L., Escher, J. C., Hojsak, I., Kolaček, S., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001896 · Cited by 191
Tang, Y., Peng, B., Liu, J., Liu, Z., Xia, Y., & Geng, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975400 · Cited by 188
“In contrast, low BMI was considered an essential risk factor for osteoporosis (1, 6), and the prevalence of postmenopausal women with osteopenia/ osteoporosis in this study differed between the BMI groups (Supplementary Table S7).”
BackgroundMethodManagement of severe osteoporosis
Miller, P. D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1124856 · Cited by 185
Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward
Khosla, S., Cauley, J. A., Compston, J., Kiel, D. P., Rosen, C., Saag, K. G., & Shane, E. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3074 · Cited by 185
Exercise Early and Often: Effects of Physical Activity and Exercise on Women’s Bone Health
Troy, K. L., Mancuso, M. E., Butler, T. A., & Johnson, J. E. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15050878 · Cited by 185
Recommendations for Evaluation and Management of Bone Disease in HIV
Brown, T. T., Hoy, J., Borderi, M., Guaraldi, G., Renjifo, B., Vescini, F., Yin, M. T., & Powderly, W. G. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ010 · Cited by 182
Fracture prediction, imaging and screening in osteoporosis
Fuggle, N. R., Curtis, E. M., Ward, K. A., Harvey, N. C., Dennison, E. M., & Cooper, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0220-8 · Cited by 182
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 178
Calcium and Bone Metabolism Indices
(2017) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2017.06.005 · Cited by 179
Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry
Leslie, W. D., Johansson, H., McCloskey, E. V., Harvey, N. C., Kanis, J. A., & Hans, D. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3538 · Cited by 177
New insights into the cellular activities of Fndc5/Irisin and its signaling pathways
Rabiee, F., Lachinani, L., Ghaedi, S., Nasr-Esfahani, M. H., Megraw, T. L., & Ghaedi, K. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00413-3 · Cited by 176
Osteosarcopenia: A case of geroscience
Kirk, B., Al Saedi, A., & Duque, G. (2019) · AGING MEDICINE · doi:10.1002/agm2.12080 · Cited by 174
A Comparison of Prediction Models for Fractures in Older Women: Is More Better?
Ensrud, K. E. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.404 · Cited by 172
Calcium and vitamin D in bone fracture healing and post-traumatic bone turnover
Institute of Orthopaedic Research and Biomechanics, U. O. U., Fischer, V, Haffner-Luntzer, M., Amling, M., & Ignatius, A. (2018) · European Cells and Materials · doi:10.22203/ecm.v035a25 · Cited by 171
Updated fracture incidence rates for the US version of FRAX®
Ettinger, B., Black, D. M., Dawson-Hughes, B., Pressman, A. R., & Melton, L. J. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1032-9 · Cited by 169
Tanaka, S., Kuroda, T., Saito, M., & Shiraki, M. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2209-1 · Cited by 165
Watts, N. B., Camacho, P. M., Lewiecki, E. M., & Petak, S. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.02.001 · Cited by 167
Self-citationCOPD and osteoporosis: links, risks, and treatment challenges
Inoue, D., Watanabe, R., & Okazaki, R. (2016) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s79638 · Cited by 167
Risk Factors for Osteoporosis in Postmenopausal Women
Bijelic, R., Milicevic, S., & Balaban, J. (2017) · Medical Archives · doi:10.5455/medarh.2017.71.25-28 · Cited by 165
Deep Learning for Osteoporosis Classification Using Hip Radiographs and Patient Clinical Covariates
Yamamoto, N., Sukegawa, S., Kitamura, A., Goto, R., Noda, T., Nakano, K., Takabatake, K., Kawai, H., Nagatsuka, H., Kawasaki, K., et al. (2020) · Biomolecules · doi:10.3390/biom10111534 · Cited by 168
“5, following World Health Organization diagnostic criteria [31].”
BackgroundCummings, S. R., Cosman, F., Lewiecki, E. M., Schousboe, J. T., Bauer, D. C., Black, D. M., Brown, T. D., Cheung, A. M., Cody, K., Cooper, C., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3039 · Cited by 165
Self-citationZheng, X., Lee, S.-K., & Chun, O. K. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.0045 · Cited by 164
PINP as a biological response marker during teriparatide treatment for osteoporosis
Krege, J. H., Lane, N. E., Harris, J. M., & Miller, P. D. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2646-0 · Cited by 162
Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010)
Griebeler, M. L., Kearns, A. E., Ryu, E., Hathcock, M. A., Melton, L. J., & Wermers, R. A. (2015) · Bone · doi:10.1016/j.bone.2014.12.003 · Cited by 163
Dual energy X-ray absorptiometry: Pitfalls in measurement and interpretation of bone mineral density
Garg, M., & Kharb, S. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.109659 · Cited by 156
Non-human primates as a model for aging
Colman, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.008 · Cited by 155
Vitamin D and chronic diseases: the current state of the art
Muscogiuri, G., Altieri, B., Annweiler, C., Balercia, G., Pal, H. B., Boucher, B. J., Cannell, J. J., Foresta, C., Grübler, M. R., Kotsa, K., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1804-x · Cited by 151
Bone Health and Osteoporosis Prevention and Treatment
MUÑOZ, M., ROBINSON, K., & Shibli-Rahhal, A. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000572 · Cited by 177
“human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone struc-”
BackgroundInfluentialGolds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Buckens, C. F. M., Dijkhuis, G. R., de Keizer, B., Verhaar, H. J. J., & de Jong, P. A. (2015) · European Radiology · doi:10.1007/s00330-014-3584-0 · Cited by 166
Briot, K., Paternotte, S., Kolta, S., Eastell, R., Reid, D. M., Felsenberg, D., Glüer, C., & Roux, C. (2013) · Bone · doi:10.1016/j.bone.2013.07.040 · Cited by 162
A decade of FRAX: how has it changed the management of osteoporosis?
Kanis, J. А., Harvey, N. C., Johansson, H., Liu, E., Vandenput, L., Lorentzon, M., Leslie, W. D., & McCloskey, E. V. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01432-y · Cited by 165
Paola, M. D., Gatti, D., Viapiana, O., Cianferotti, L., Cavalli, L., Caffarelli, C., Conversano, F., Quarta, E., Pisani, P., Girasole, G., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4686-3 · Cited by 168
Trends and Disparities in Osteoporosis Screening Among Women in the United States, 2008-2014
Gillespie, C. W., & Morin, P. E. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.10.018 · Cited by 147
Osteoporosis Is Common and Undertreated Prior to Total Joint Arthroplasty
Bernatz, J. T., Brooks, A. E., Squire, M. W., Illgen, R. L., Binkley, N., & Anderson, P. A. (2019) · The Journal of Arthroplasty · doi:10.1016/j.arth.2019.03.044 · Cited by 148
Salzmann, S. N., Okano, I., Jones, C., Zhu, J., Lu, S., Onyekwere, I., Balaji, V., Reisener, M., Chiapparelli, E. A., Shue, J., et al. (2022) · The Spine Journal · doi:10.1016/j.spinee.2022.03.006 · Cited by 157
Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis
Keaveny, T., Clarke, B., Cosman, F., Orwoll, E., Siris, E., Khosla, S., & Bouxsein, M. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05384-2 · Cited by 117
Self-citationRisk of imminent fracture following a previous fracture in a Swedish database study
Banefelt, J., Åkesson, K., Spångéus, A., Ljunggren, Ö., Karlsson, L. K., Ström, O., Ortsäter, G., Libanati, C. R., & Tóth, E. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04852-8 · Cited by 145
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women
Greenspan, S. L., Perera, S., Ferchak, M. A., Nace, D. A., & Resnick, N. M. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0747 · Cited by 145
Lems, W. F., Paccou, J., Zhang, J., Fuggle, N. R., Chandran, M., Harvey, N. C., Cooper, C. C., Javaid, M. K., Ferrari, S., Åkesson, K., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-020-05804-3 · Cited by 160
“Lastly, the National Osteoporosis Foundation (NOF) released, in 2014, a clinician’s guide to prevention and treatment of osteoporosis including indications for vertebral imaging [107].”
MethodSelf-citationZysset, P., Qin, L., Lang, T., Khosla, S., Leslie, W., Shepherd, J. A., Schousboe, J., & Engelke, K. (2015) · Journal of clinical densitometry · doi:10.1016/j.jocd.2015.06.011 · Cited by 126
Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products
Chiang, S., & Pan, T. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3753-x · Cited by 158
Osteoporosis and Its Complications
Varacallo, M. A., & Fox, E. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.03.007 · Cited by 151
Humbert, L., Martelli, Y., Fonollá, R., Steghofer, M., Gregorio, S. D., Malouf, J., Romera, J., & Barquero, L. M. D. R. (2017) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2593346 · Cited by 130
Wright, N. C., Saag, K. G., Dawson-Hughes, B. F., Khosla, S., & Siris, E. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3865-3 · Cited by 143
Blain, H., Masud, T., Dargent-Molina, P., Martin, F. C., Rosendahl, E., van der Velde, N., Bousquet, J., Benetos, A., Cooper, C., Kanis, J. A., et al. (2016) · The Journal of nutrition, health and aging · doi:10.1007/s12603-016-0741-y · Cited by 133
Jin, S., Hsieh, E., Li, P., Yu, C., Wang, Y.-Y.-Q., Wu, C., Wang, Q., Li, K., & Zeng, X. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4473-1 · Cited by 151
Intervention Thresholds and the Diagnosis of Osteoporosis
Kanis, J. А., McCloskey, E. V., Harvey, N. C., Johansson, H., & Leslie, W. D. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2531 · Cited by 138
Fall Prevention in Community-Dwelling Older Adults
Phelan, E. A., & Ritchey, K. C. (2018) · Annals of Internal Medicine · doi:10.7326/aitc201812040 · Cited by 148
Developing Consensus Criteria for Sarcopenia: An Update
McLean, R. R., & Kiel, D. P. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2492 · Cited by 129
Cosman, F., Cauley, J. A., Eastell, R., Boonen, S., Palermo, L., Reid, I. R., Cummings, S. R., & Black, D. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1971 · Cited by 129
Self-citationEngelke, K., Lang, T., Khosla, S., Qin, L., Zysset, P. K., Leslie, W. D., Shepherd, J., & Schousboe, J. T. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.06.010 · Cited by 129
Aljohani, S., Fliefel, R. M., Ihbe, J., Kühnisch, J., Ehrenfeld, M., & Otto, S. (2017) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2017.05.028 · Cited by 137
Management of Osteoporosis in CKD
Khairallah, P., & Nickolas, T. L. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11031017 · Cited by 137
Penoni, D. C., Fidalgo, T. K. S., Torres, S. R., Varela, V. M., Masterson, D., Leão, A. T. T., & Maia, L. C. (2017) · Journal of Dental Research · doi:10.1177/0022034516682017 · Cited by 126
Golob, A. L., & Laya, M. B. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.01.010 · Cited by 164
Cosman, F., Krege, J. H., Looker, A. C., Schousboe, J. T., Fan, B., Sarafrazi, N., Shepherd, J., Krohn, K., Steiger, P., Wilson, K. E., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3948-9 · Cited by 136
Self-citationOsteosarcopenic Obesity: Current Knowledge, Revised Identification Criteria and Treatment Principles
Kelly, O. J., Gilman, J. C., Boschiero, D., & Ilich, J. Z. (2019) · Nutrients · doi:10.3390/nu11040747 · Cited by 126
Anabolic Therapies in Osteoporosis and Bone Regeneration
Rußow, G., Jahn, D., Appelt, J., Märdian, S., Tsitsilonis, S., & Keller, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010083 · Cited by 135
Dietary Protein Intake above the Current RDA and Bone Health: A Systematic Review and Meta-Analysis
Wallace, T. C., & Frankenfeld, C. L. (2017) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1322924 · Cited by 123
Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss
Weske, S., Vaidya, M., Reese, A., Lipinski, K. V. W., Keul, P., Bayer, J. K., Fischer, J. W., Flögel, U., Nelsen, J., Epple, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0005-y · Cited by 131
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 128
A Guide to Improving the Care of Patients With Fragility Fractures
Bukata, S. V., DiGiovanni, B. F., Friedman, S. M., Hoyen, H. A., Kates, A., Kates, S. L., Mears, S. C., Mendelson, D. A., Serna, F. H., Sieber, F. E., et al. (2011) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458510397504 · Cited by 139
Brown, T. T., Moser, C., Currier, J. S., Ribaudo, H. J., Rothenberg, J., Kelesidis, T., Yang, O. O., Dubé, M. P., Murphy, R. L., Stein, J. H., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv194 · Cited by 132
Targeting Macrophages: Friends or Foes in Disease?
Ardura, J. A., Rackov, G., Izquierdo, E., Alonso, V., Gortázar, A. R., & Escribese, M. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01255 · Cited by 134
“Osteoporosis is a chronic bone disease characterized by an increased risk of fracture due to the degradation of bone tissue (resorption) by overactivated monocyte-derived osteoclasts, being a leading cause of mortality in the elderly (Cosman et al., 2014).”
BackgroundLeBoff, M. S., Chou, S. H., Murata, E. M., Donlon, C. M., Cook, N. R., Mora, S., Lee, I.-M., Kotler, G., Bubes, V., Buring, J. E., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3958 · Cited by 120
Self-citationOsteoporosis-associated Fracture and Diabetes
Kurra, S., Fink, D. A., & Siris, E. S. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.004 · Cited by 133
Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population
Williams, S. A., Daigle, S. G., Weiss, R., Wang, Y., Arora, T., & Curtis, J. R. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020970518 · Cited by 128
Dagan, N., Cohen-Stavi, C., Leventer-Roberts, M., & Balicer, R. D. (2017) · BMJ · doi:10.1136/bmj.i6755 · Cited by 118
Pharmacological treatment of osteoporosis in the oldest old
Vandenbroucke, A.-M., Luyten, F., Flamaing, J., & Gielen, E. (2017) · Clinical Interventions in Aging · doi:10.2147/cia.s131023 · Cited by 118
Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review
Martinis, M. D., Allegra, A., Sirufo, M. M., Tonacci, A., Pioggia, G., Raggiunti, M., Ginaldi, L., & Gangemi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168855 · Cited by 154
Deardorff, W. J., Cenzer, I. S., Nguyen, B., & Lee, S. J. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6745 · Cited by 146
Kanis, J. А., Harvey, N. C., Johansson, H., Odén, A., Leslie, W. D., & McCloskey, E. V. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.022 · Cited by 137
Shared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Use of dienogest in endometriosis: a narrative literature review and expert commentary
Murji, A., Biberoğlu, K., Leng, J., Mueller, M. D., Römer, T., Vignali, M., & Yarmolinskaya, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1744120 · Cited by 116
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 160
Sukegawa, S., Fujimura, A., Taguchi, A., Yamamoto, N., Kitamura, A., Goto, R., Nakano, K., Takabatake, K., Kawai, H., Nagatsuka, H., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10150-x · Cited by 142
Yazdany, J., Schmajuk, G., Robbins, M., Daikh, D., Beall, A., Yelin, E. H., Barton, J. L., Carlson, A., Margaretten, M. E., Zell, J., et al. (2013) · Arthritis Care & Research · doi:10.1002/acr.21930 · Cited by 124
Solomon, D. H., Patrick, A. R., Schousboe, J. T., & Losina, E. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2180 · Cited by 118
Adams, A. L., Fischer, H. J., Kopperdahl, D. L., Lee, D. C., Black, D. M., Bouxsein, M., Fatemi, S., Khosla, S., ORWOLL, E. S., Siris, E. S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3423 · Cited by 125
Skeletal effects of nutrients and nutraceuticals, beyond calcium and vitamin D
Nieves, J. W. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2214-4 · Cited by 135
Collins, G. S., Mallett, S., & Altman, D. G. (2011) · BMJ · doi:10.1136/bmj.d3651 · Cited by 114
Balasubramanian, A., Tosi, L. L., Lane, J. M., Dirschl, D. R., Ho, P., & O’Malley, C. D. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01781 · Cited by 114
Current Management of Short Bowel Syndrome
Thompson, J. S., Rochling, F. A., Weseman, R. A., & Mercer, D. F. F. (2012) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2011.10.002 · Cited by 129
Musculoskeletal exercise: Its role in promoting health and longevity
D’Onofrio, G., Kirschner, J. S., Prather, H., Goldman, D., & Rozanski, A. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.006 · Cited by 147
X-ray-based quantitative osteoporosis imaging at the spine
Löffler, M. T., Sollmann, N., Mei, K., Valentinitsch, A., Noël, P. B., Kirschke, J. S., & Baum, T. (2020) · Osteoporosis International · doi:10.1007/s00198-019-05212-2 · Cited by 114
The crosstalk between bone remodeling and energy metabolism: A translational perspective
Karsenty, G., & Khosla, S. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.04.010 · Cited by 113
Valderrábano, R. J., & Linares, M. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0060-9 · Cited by 127
Lorentzon, M., Branco, J., Brandi, M. L., Bruyère, O., Chapurlat, R. D., Cooper, C. C., Cortet, B., Díez‐Pérez, A., Ferrari, S., Gáspárik, A. I., et al. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01063-9 · Cited by 132
Okazaki, R., Ozono, K., Fukumoto, S., et al. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0805-4 · Cited by 112
Osteoporosis in Older Persons: Old and New Players
Zanker, J., & Duque, G. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15716 · Cited by 112
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns
Dawson-Hughes, B. F., Looker, A. C., Tosteson, A. N. A., Johansson, H., Kanis, J. А., & Melton, L. J. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1034-7 · Cited by 115
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.